A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)

Inclusion Criteria: * Histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ function Exclusion Criteria: * Chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies) within 4 weeks prior to drug administration (6 weeks for nitrosoureas or mitomycin C) or not recovered from adverse events due to agents administered more than 4 weeks earlier * Primary central nervous system (CNS) tumor * Active CNS metastases and/or carcinomatous meningitis * Known hypersensitivity to the components of the study therapy or its analogs * Recent history of abdominal surgery or peritonitis * Bowel occlusion or sub occlusion * Prior abdominal or pelvis radiation therapy or radiation therapy to \> 10% of the bone marrow at any time in the past or prior radiation therapy within the last three years to the breast / sternum, head, or neck * Requires anti-folate therapy * Symptomatic ascites or pleural effusion * Prior stem cell or bone marrow transplant